Overview

A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of FAB122 in Patients With Amyotrophic Lateral Sclerosis

Status:
Recruiting

Trial end date:
2024-06-20

Target enrollment:

Participant gender:

Summary

Multicenter, multinational, double-blind, randomized (2:1), placebo-controlled Phase III study to investigate the efficacy and safety of 100 mg FAB122 once daily as oral formulation in ALS patients.

Phase:

Phase 3

Details

Lead Sponsor:

Ferrer Internacional S.A.

Collaborators:

Julius Clinical, The Netherlands
Stichting TRICALS Foundation